GlassScriptPhysician profile
Katara S Chavis
NPI 1245532423
$2,035.00
in general payments reported to CMS, 2019-2025
27 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $460 · 2022: $314 · 2023: $495 · 2024: $430 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $346.72 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $278.00 | 2021-2025 | |
| Novo Nordisk INC | $186.12 | 2022-2025 | Wegovy |
| Amgen INC. | $181.87 | 2021-2025 | Repatha, Otezla, Krystexxa |
| Idorsia Pharmaceuticals US INC | $134.13 | 2023 | Quviviq |
| Lilly USA, LLC | $121.52 | 2021-2023 | Reyvow, Emgality, Mounjaro |
| Ardelyx, INC. | $116.06 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.63 | 2021-2024 | Relistor |
| Bayer Healthcare Pharmaceuticals INC. | $78.21 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.78 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $48.77 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $44.44 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.51 | 2023 | |
| Pfizer INC. | $32.55 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.40 | 2021-2023 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.55 | 2022 | |
| Corium, LLC | $30.53 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $26.02 | 2023 | Auvelity |
| Jazz Pharmaceuticals INC. | $25.02 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $20.00 | 2025 | Purified Cortrophin Gel |
| Optinose US, INC. | $17.88 | 2021 | |
| Fresenius USA Marketing, INC. | $17.69 | 2025 | Velphoro |
| Biohaven Pharmaceutical Holding Company LTD. | $16.51 | 2022 | |
| Corcept Therapeutics | $16.41 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $15.01 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.00 | 2022 | |
| Esperion Therapeutics, INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katara Chavis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.